Access the full text.
Sign up today, get DeepDyve free for 14 days.
Qiang Zhou, Yongjing Cheng, Houshan Lü, Wei-Hong Zhou, Z. Li (2003)
Inhibition of T-cell activation with HLA-DR1/DR4 restricted Non-T-cell stimulating peptides.Human immunology, 64 9
B. Bielekova, Roland Martin (2001)
Antigen-specific immunomodulation via altered peptide ligandsJournal of Molecular Medicine, 79
Y. Ohnishi, A. Tsutsumi, I. Matsumoto, D. Goto, S. Ito, M. Kuwana, Y. Uemura, Y. Nishimura, T. Sumida (2006)
Altered peptide ligands control type II collagen-reactive T cells from rheumatoid arthritis patientsModern Rheumatology, 16
T. Mosmann, R. Coffman (1989)
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.Annual review of immunology, 7
M. Levings, S. Allan, Eva d’Hennezel, C. Piccirillo (2006)
Functional dynamics of naturally occurring regulatory T cells in health and autoimmunity.Advances in immunology, 92
Alexander LeGrand, B. Fermor, C. Fink, D. Pisetsky, J. Weinberg, T. Vail, F. Guilak (2001)
Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci.Arthritis and rheumatism, 44 9
S. Brocke, K. Gijbels, M. Allegretta, I. Ferber, C. Piercy, Thomas Blankensteini, Roland Martin, U. Utz, N. Karin, D. Mitchell, T. Veromaa, A. Waisman, A. Gaur, P. Conlon, N. Ling, P. Fairchild, D. Wraith, A. O’Garra, C. Fathman, L. Steinman (1996)
Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic proteinNature, 379
L. Harrington, R. Hatton, Paul Mangan, H. Turner, T. Murphy, K. Murphy, C. Weaver (2005)
Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNature Immunology, 6
D. Jovanovic, J. Battista, J. Martel-Pelletier, F. Jolicoeur, Yulan He, Mengkun Zhang, F. Mineau, J. Pelletier (1998)
IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL-β and TNF-α, by Human MacrophagesThe Journal of Immunology
Y. Waksman, I. Hod, A. Friedman (1996)
Therapeutic effects of estradiol benzoate on development of collagen‐induced arthritis (CIA) in the Lewis rat are mediated via suppression of the humoral response against denatured collagen type II (CII)Clinical & Experimental Immunology, 103
H. Ben-David, M. Sela, E. Mozes (2005)
Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis.Proceedings of the National Academy of Sciences of the United States of America, 102 6
Zhong-qiang Yao, Ru Li, Zhanguo Li (2007)
A triple altered collagen II peptide with consecutive substitutions of TCR contacting residues inhibits collagen-induced arthritisAnnals of the Rheumatic Diseases, 66
Kanp-Sung Kim, Yoo-Haeng Choi, Kyung-Ho Kim, Young-Choon Lee, Cheorl-Ho Kim, S. Moon, Seung-Goo Kang, Young‐Guk Park (2004)
Protective and anti-arthritic effects of deer antler aqua-acupuncture (DAA), inhibiting dihydroorotate dehydrogenase, on phosphate ions-mediated chondrocyte apoptosis and rat collagen-induced arthritis.International immunopharmacology, 4 7
Q Zhou, YJ Cheng, H Lü, WH Zhou, ZG Li (2003)
Inhibition of T cell activation with HLA-DR1/DR4 restricted non-T cell recognizing peptidesHum Immunol, 64
M. Nishikawa, A. Myoui, T. Tomita, K. Takahi, A. Nampei, H. Yoshikawa (2003)
Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653.Arthritis and rheumatism, 48 9
Chia-Rui Shen, Abdel-Rahman Youssef, Anne Devine, L. Bowie, A. Hall, D. Wraith, C. Elson, R. Barker (2003)
Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia.Blood, 102 10
L. Myers, Y. Sakurai, E. Rosloniec, J. Stuart, A. Kang (2004)
An Analog Peptide that Suppresses Collagen‐Induced ArthritisThe American Journal of the Medical Sciences, 327
Y. Sakurai, D. Brand, B. Tang, E. Rosloniec, J. Stuart, A. Kang, L. Myers (2006)
Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic miceArthritis Research & Therapy, 8
B. Prakken, S. Roord, P. Kooten, J. Wagenaar, W. Eden, S. Albani, M. Wauben (2002)
Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope.Arthritis and rheumatism, 46 7
K. Bush, K. Farmer, J. Walker, B. Kirkham (2002)
Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein.Arthritis and rheumatism, 46 3
J. Penzotti, G. Nepom, Terry Lybrand (1997)
Use of T cell receptor/HLA-DRB1*04 molecular modeling to predict site-specific interactions for the DR shared epitope associated with rheumatoid arthritis.Arthritis and rheumatism, 40 7
Ru Li, Xia Li, Zhanguo Li (2006)
Altered collagen II peptides inhibited T-cell activation in rheumatoid arthritis.Clinical immunology, 118 2-3
D. Jovanovic, J. Martel-Pelletier, J. Battista, F. Mineau, F. Jolicoeur, M. Benderdour, J. Pelletier (2000)
Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis.Arthritis and rheumatism, 43 5
Erik Lubberts, Leo Joosten, F. Loo, P. Schwarzenberger, Jay Kolls, W. Berg (2002)
Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destructionInflammation Research, 51
D. Jovanovic, J. Battista, J. Martel-Pelletier, F. Jolicoeur, Yulan He, Mengkun Zhang, F. Mineau, J. Pelletier (1998)
IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.Journal of immunology, 160 7
Heon Park, Zhaoxia Li, Xuexian Yang, S. Chang, R. Nurieva, Yi-hong Wang, Ying Wang, L. Hood, Zhou Zhu, Qiang Tian, C. Dong (2005)
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17Nature Immunology, 6
D. Alleva, A. Gaur, Li-Qin Jin, D. Wegmann, P. Gottlieb, A. Pahuja, Eric Johnson, T. Motheral, A. Putnam, P. Crowe, N. Ling, S. Boehme, P. Conlon (2002)
Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide.Diabetes, 51 7
M. Chabaud, P. Garnero, J. Dayer, P. Guerne, F. Fossiez, P. Miossec (2000)
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis.Cytokine, 12 7
L. Santambrogio, M. Lees, R. Sobel (1998)
Altered peptide ligand modulation of experimental allergic encephalomyelitis: immune responses within the CNSJournal of Neuroimmunology, 81
M. Ehrenstein, Jamie Evans, Animesh Singh, S. Moore, G. Warnes, D. Isenberg, C. Mauri (2004)
Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα TherapyThe Journal of Experimental Medicine, 200
B. Berner, D. Akça, T. Jung, G. Müller, M. Reuss-Borst (2000)
Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.The Journal of rheumatology, 27 5
H. Wu, F. Ward, N. Staines (2002)
Histone Peptide-Induced Nasal Tolerance: Suppression of Murine Lupus1The Journal of Immunology, 169
Bi Li (2006)
Foxp3 expression of regulatory T cells in rheumatoid arthritisChinese journal of immunology
Ru Li, Xia Li, Ping Li, Zhong-qiang Yao, Jia Guo, Zhanguo Li (2006)
[Effect of multiple amino acid substitutions of collagen II 263-272 on collagen-induced arthritis].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 38 4
P. Mukherjee, Bin Wu, L. Mayton, Seon Kim, Paul Robbins, P. Wooley (2003)
TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritisAnnals of the Rheumatic Diseases, 62
A. Vanderborght, P. Geusens, J. Raus, P. Stinissen (2001)
The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies.Seminars in arthritis and rheumatism, 31 3
M. Chabaud, J. Durand, N. Buchs, F. Fossiez, G. Page, L. Frappart, P. Miossec (1999)
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium.Arthritis and rheumatism, 42 5
L. Myers, Y. Sakurai, B. Tang, Xiaowen He, E. Rosloniec, J. Stuart, A. Kang (2002)
Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice.Arthritis and rheumatism, 46 12
Yong-Jing Cheng, Qiang Zhou, Zhi-Ying Li (2005)
The Inhibitory Effect of Altered Collagen II Peptide on HLA‐DRB1‐Restricted T‐Cell ActivationScandinavian Journal of Immunology, 61
Q. Tang, J. Bluestone (2006)
Regulatory T‐cell physiology and application to treat autoimmunityImmunological Reviews, 212
L. Stamp, M. James, L. Cleland (2004)
Interleukin‐17: the missing link between T‐cell accumulation and effector cell actions in rheumatoid arthritis?Immunology and Cell Biology, 82
S. Nakae, Aya Nambu, K. Sudo, Y. Iwakura (2003)
Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice 1The Journal of Immunology, 171
Rheumatoid arthritis (RA) is a systemic autoimmune disease mediated by T cells. Collagen type II (CII) is one of the autoantigens associated with RA. CII263-272 is a predominant CII antigenic peptide that can induce T-cell activation upon binding to MHC and interaction with the appropriate T-cell receptor (TCR). Altered CII263-272 peptides with substitution of specific amino acids could bind to RA-associated HLA-DR4/1 with no T cell stimulating effects and could inhibit T cell activation in RA. We performed this study to evaluate the effect of mucosal administration and to explore the mechanism of the inhibitory effect of altered CII263-272 peptide (267Q → A, 270K → A and 271G → A) on collagen induced arthritis (CIA). CIA was induced in Lewis rats by immunization with bovine CII. Altered CII263-272 peptide was given intranasally beginning from arthritis onset. Wild CII263-272 peptide or PBS was administered as controls. Therapeutic effects were evaluated by arthritis scores, body weight change, and joint pathologic scores. The anti-CII antibody and its subtypes and the cytokines, IFN-γ, IL-10, and IL-17 were measured with ELISA. Foxp3+CD4+CD25+ regulatory T cell induction was assessed by FACS analysis. Following treatment with the altered CII263-272 peptide, arthiritis scores were reduced and body weight was increased. The altered CII263-272 peptide could retard the histologic lesion of the joints. The titers of anti-CII antibodies IgG2a in altered CII263-272 peptide treated rats decreased markedly compared to PBS-treated rats. The serum levels of IFN-γ in rats treated with altered peptide was lower than that of rats treated with wild CII263-272 peptide and PBS. No differences were observed in the levels of serum IL-10 among the three groups. The altered CII263-272 peptide could decrease serum level of IL-17 and increase peripheral Foxp3+CD4+CD25+ T cells at early stage of CIA. Mucosal administration of altered CII263-272 peptide could effectively inhibit the progression of CIA. Altered CII263-272 peptide could suppress Th17 cells and expand regulatory T cells in the early stage of the disease. The IgG2a subtype of anti-CII antibodies and IFN-γ were reduced and in vivo Th1 responses were inhibited as a result of altered CII peptide treatment. Altered CII peptide is likely therapeutic in RA.
Rheumatology International – Springer Journals
Published: Jul 5, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.